AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
NEW YORK, April 11, 2018 -- Safirstein Metcalf LLP, announces that a class action lawsuit was filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Cancer Genetics, Inc. (NASDAQ:CGIX) (“Cancer Genetics” or the “Company”) securities between March 23, 2017 and April 2, 2018 (the “Class Period”).
If you purchased or acquired Cancer Genetics securities during the class period, and would like more information about the shareholder class action, please contact Safirstein Metcalf LLP at 1-800-221-0015, or email [email protected]
If you wish to serve as lead plaintiff, you must move the Court no later than June 4, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.
According to the complaint, the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On April 2, 2018, the Company reported that, following its CEO’s departure, it conducted a comprehensive review of its strategy and organization. This led the Company to record a bad debt expense of $4.4 million and write off $1.8 million of its accounts receivable in the fourth quarter, with a significant portion related to collection issues with accounts receivables recorded after 2015. The Company also reported that, on December 31, 2017, its “cash position and history of losses required management to assess [its] ability to continue operating as a going concern[.]” Following this news, shares of Cancer Genetics fell $0.55 per share or over 33% to close at $1.10 per share on April 3, 2018.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP
Peter Safirstein, Esq.
1250 Broadway
27th Floor
New York, NY 10001
1-800-221-0015
